- Home
- ARWR vs IMCR Comparison
ARWR vs IMCR Comparison
Compare ARWR & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- IMCR
- Stock Information
- Founded
- ARWR 2003
- IMCR 2008
- Country
- ARWR United States
- IMCR United Kingdom
- Employees
- ARWR N/A
- IMCR N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARWR Health Care
- IMCR Health Care
- Exchange
- ARWR Nasdaq
- IMCR Nasdaq
- Market Cap
- ARWR 1.8B
- IMCR 1.6B
- IPO Year
- ARWR 1993
- IMCR 2021
- Fundamental
- Price
- ARWR $18.31
- IMCR $35.00
- Analyst Decision
- ARWR Buy
- IMCR Buy
- Analyst Count
- ARWR 8
- IMCR 10
- Target Price
- ARWR $43.71
- IMCR $58.13
- AVG Volume (30 Days)
- ARWR 1.6M
- IMCR 383.2K
- Earning Date
- ARWR 08-07-2025
- IMCR 08-07-2025
- Dividend Yield
- ARWR N/A
- IMCR N/A
- EPS Growth
- ARWR N/A
- IMCR N/A
- EPS
- ARWR N/A
- IMCR N/A
- Revenue
- ARWR $545,209,000.00
- IMCR $333,581,000.00
- Revenue This Year
- ARWR $21,924.50
- IMCR $26.82
- Revenue Next Year
- ARWR N/A
- IMCR $8.15
- P/E Ratio
- ARWR N/A
- IMCR N/A
- Revenue Growth
- ARWR 1436.97
- IMCR 25.75
- 52 Week Low
- ARWR $9.57
- IMCR $23.15
- 52 Week High
- ARWR $30.41
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- ARWR 66.51
- IMCR 59.78
- Support Level
- ARWR $16.45
- IMCR $32.20
- Resistance Level
- ARWR $19.24
- IMCR $35.75
- Average True Range (ATR)
- ARWR 0.79
- IMCR 1.31
- MACD
- ARWR 0.25
- IMCR 0.28
- Stochastic Oscillator
- ARWR 77.43
- IMCR 84.94
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.